SPRY Key Statistics, Chart & Performance
The current stock price of SPRY is 11.32 USD. In the past month the price increased by 10.03%. In the past year, price decreased by -2.4%.
SPRY Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.64 | 394.90B | ||
| AMGN | AMGEN INC | 15.06 | 177.31B | ||
| GILD | GILEAD SCIENCES INC | 14.88 | 151.17B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.76 | 117.88B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.14 | 81.10B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 796.99 | 53.70B | ||
| INSM | INSMED INC | N/A | 37.27B | ||
| NTRA | NATERA INC | N/A | 34.18B | ||
| BIIB | BIOGEN INC | 10.82 | 26.58B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.15 | 21.76B | ||
| INCY | INCYTE CORP | 16.65 | 20.99B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.30B |
Related stock screener links
About SPRY
Company Profile
ARS Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of a novel, potentially first-in-class product candidate, neffy, for the emergency treatment of Type I allergic reactions including anaphylaxis. The company is headquartered in San Diego, California and currently employs 162 full-time employees. The company went IPO on 2020-12-04. The firm is focused on the commercialization and development of neffy for the needle-free intranasal delivery of epinephrine for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an innovative absorption enhancer called Intravail, which allows neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.
Company Info
ARS PHARMACEUTICALS INC
11682 El Camino Real, Suite 300
San Diego CALIFORNIA US
Employees: 162
Phone: 18587719307
ARS PHARMACEUTICALS INC / SPRY FAQ
Can you describe the business of ARS PHARMACEUTICALS INC?
ARS Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of a novel, potentially first-in-class product candidate, neffy, for the emergency treatment of Type I allergic reactions including anaphylaxis. The company is headquartered in San Diego, California and currently employs 162 full-time employees. The company went IPO on 2020-12-04. The firm is focused on the commercialization and development of neffy for the needle-free intranasal delivery of epinephrine for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an innovative absorption enhancer called Intravail, which allows neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.
Can you provide the latest stock price for ARS PHARMACEUTICALS INC?
The current stock price of SPRY is 11.32 USD. The price increased by 3.19% in the last trading session.
What is the dividend status of ARS PHARMACEUTICALS INC?
SPRY does not pay a dividend.
How is the ChartMill rating for ARS PHARMACEUTICALS INC?
SPRY has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the analyst forecast for SPRY stock?
12 analysts have analysed SPRY and the average price target is 28.39 USD. This implies a price increase of 150.8% is expected in the next year compared to the current price of 11.32.
How is the valuation of ARS PHARMACEUTICALS INC (SPRY) based on its PE ratio?
ARS PHARMACEUTICALS INC (SPRY) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.84).
How many employees does ARS PHARMACEUTICALS INC have?
ARS PHARMACEUTICALS INC (SPRY) currently has 162 employees.
SPRY Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to SPRY. When comparing the yearly performance of all stocks, SPRY is a bad performer in the overall market: 71.34% of all stocks are doing better.
SPRY Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SPRY. The financial health of SPRY is average, but there are quite some concerns on its profitability.
SPRY Financial Highlights
Over the last trailing twelve months SPRY reported a non-GAAP Earnings per Share(EPS) of -0.84. The EPS decreased by -64.71% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -21.47% | ||
| ROE | -54.21% | ||
| Debt/Equity | 0.65 |
SPRY Forecast & Estimates
12 analysts have analysed SPRY and the average price target is 28.39 USD. This implies a price increase of 150.8% is expected in the next year compared to the current price of 11.32.
For the next year, analysts expect an EPS growth of -3625.79% and a revenue growth 339.69% for SPRY